Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Predictive Response Factors in Respondent Patients and Results After Monoplane Switch in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05078281

Acronym

Asthma

Enrollment

Registered

2021-10-14

Start date

2020-11-01

Completion date

2022-04-01

Last updated

2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma; Eosinophilic

Brief summary

Retrospective, multicenter, routine clinical practice study with consecutive inclusion of adult patients with severe eosinophilic asthma receiving benralizumab treatment.

Detailed description

Retrospective study studying severe eosinophilic asthma. Patients with this disease who are on benralizumab treatment for at least 4 months before the start of the study will be included. The purpose of this study is to analyze the predictive factors of response in patients with this type of disease treated with benralizumab, who obtain a complete response during their follow-up. The results of the study will be obtained through the review of medical records, where demographic characteristics such as age, gender and smoking will be assessed; presence of comorbidities; clinical-functional variables; response variables (exercises, cycles of oral corticosteroids, admissions, visits to the emergency room or unscheduled, cumulative dose of oral corticosteroids, absenteeism from work) and side effects.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (over 18 years of age) diagnosed with severe eosinophilic asthma on benralizumab treatment for at least 4 months from the start of the study.

Exclusion criteria

* Patients for whom no previous history is available or who do not meet the inclusion criteria.

Design outcomes

Primary

Measure	Time frame	Description
Response predictors in patients treated with benralicumab.	Up to 60 weeks.	To analyze response predictors in patients with severe eosinophilic asthma under treatment with benralizumab who obtain a complete response during their follow-up.

Secondary

Measure	Time frame	Description
Study the response variables to benralizumab.	Up to 60 weeks.	Number of visits to the emergency room or hospital admissions observed since the beginning of the study.

Countries

Spain

Contacts

Primary ContactAna Gómez-Ballesteros Fernández

ana.gomezbastero@gmail.com955008000

Backup ContactCarlos García Perez

administracion.eecc.hvm.sspa@juntadeandalucia.es600162458

Outcome results